Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label randomized dose-response study of atomoxetine in Korean pediatric ADHD outpatients
2017-000685-29Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-response in ADHDRS-IV-Parent:Inv total score.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2017-000685-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000685-29.